HTB

Paediatric care

Paediatric formulations of ARVs: including an exciting new class

Lower malaria risk in children receiving lopinavir/ritonavir-based compared to NNRTI-based ART

High prevalence of d4T-associated lipodystrophy including lipoatrophy in children

Lopinavir/ritonavir monotherapy in children

Stopping treatment after early ART in infants

FDA approves etravirine for treatment-experienced children 6 to 18 years of age and new scored 25 mg tablet for paediatric dosing

Delaying ART in childhood can reduce long-term CD4 count in adulthood

Efavirenz under-dosing in children

Treatment response and duration of first line treatment in European infants

Pharmacokinetics of paediatric tenofovir based regimens

Atazanavir pharmacokinetics in infants, children and adolescents

Crushing lopinavir/ritonavir tablets decreases exposure by almost half in children

No difference in AIDS-free survival in children starting ART with a CD4% between 15%–24% compared to deferring until less than 15% in the PREDICT trial

Paediatric antiretroviral pipeline: update on etravirine and maraviroc

Prematurity not associated with early mortality in infants on ART

More metabolic abnormalities in children receiving a PI compared to NNRTI in NEVEREST study

Treating children previously exposed to single dose nevirapine: update on IMPAACT P1060 and NEVEREST

Lopinavir/ritonavir oral solution toxicity in neonates

Paediatric antiretroviral pipeline: darunavir and raltegravir

The paediatric antiretroviral pipeline

Health outcomes for young adults with perinatally acquired HIV infection following transfer to adult services

Lopinavir troughs lower in children on once-daily dose with efavirenz

Long-term outcomes for infants starting lopinavir/ritonavir at less than 6 months

Effects of antiretroviral exposure through PMTCT strategies on infants in Botswana

Pharmacokinetics of lopinavir/ritonavir incombination with rifampicin based TB treatment in children

Initiating nevirapine with fixed dose combination “mini-pills” in Zambia

Early infant diagnosis

US paediatric guidelines updated (August 2010)

Daily cotrimoxazole preferable to intermittent preventative therapy inHIV-infected children

New WHO guidelines for children (July 2010)

Early treatment for infants is cost-effective

No difference in outcomes for children initiating treatment with a protease inhibitor or an NNRTI nor with viral load switching strategies in PENPACT-1

Tablets more acceptable than syrups in the ARROW trial

Paediatric formulation of TMC 278

Atazanavir/r approved in Europefor children aged 6 to 18 years

FDA finally approves 4th generation HIV Ag/Ab test in the US

Paediatric antiretroviral pipeline

Significant rates of unplanned pregnancies among young women born with HIV

75% HIV-positive children have insufficient levels of Vitamin D

Poor bioequivalence with crushed and dissolved tablets

Initial PK, safety and 12 week efficacy of raltegravir chewable tablets in children 6-11 years

PK of efavirenz in children dosed according to WHO weight bands

Virological and immunological responses in infants enrolled in the CHER trial

Darunavir-associated mutations in PI-naive and PI-experienced children in the UK

Pregnancy outcomes in infants exposed to maternal antiretrovirals in utero

Infant feeding in the UK (2010): draft guidelines online for comment

Pilot PK study of two generic paediatric formulations of lopinavir/ritonavir vs originator products

Lipodystrophy is common in children from three European cohorts

Early infant diagnosis

Difficulties with implementation

Infant outcomes

Improved neurodevelopmental outcomes

Treating children exposed to single dose nevirapine for PMTCT

Using a nevirapine-containing fixed dose combination in the CHAPAS trial

Once a day lamivudine and abacavir, and abacavir hypersensitivity in the ARROW trial

HIV, the brain and children

Pregnancy outcomes in HAART exposed infants in Johannesburg

Treating children previously exposed to single dose nevirapine

Population pharmacokinetic model of nevirapine maternal to infant transfer through breastfeeding

Phenotypic and genotypic inhibitory quotients and virologic response in treatment experienced children

Tenofovir pharmacokinetics in three tenofovir-containing regimens in children and adolescents

Pharmacokinetic studies in very young infants

Double-dose lopinavir/ritonavir provides insufficient lopinavir exposure in children receiving rifampicin

PI-based ART in children with HIV and HIV/TB coinfection in South Africa

Etravirine dose selection in children aged 6 to 17

Post navigation